Drugs / IM96 CAR-T Cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05287165 | Mar 2022 → Apr 2024 | colorectal cancer, pancreas disorder | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07406984 | Mar 2026 → May 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06718738 | Dec 2024 → Aug 2025 overdue | colorectal cancer | Beijing Immunochina Medical Science & Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM96 CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07406984 ↗ |
| Modality | Cell therapy | “a chimeric antigen receptor T (CAR T) cell targeting guanylyl cyclase 2C (GUCY2C)” PMID 42241671 ↗ Jun 2026 |
| Target | GUCY2C | “a chimeric antigen receptor T (CAR T) cell targeting guanylyl cyclase 2C (GUCY2C)” PMID 42241671 ↗ Jun 2026 |